MedImmune snaps up beta cell regeneration portfolio from Evotec
This article was originally published in Scrip
Through its subsidiary Develogen, Evotec has signed over exclusive access to its research portfolio focused on the regeneration of insulin producing beta cells to treat diabetes to MedImmune (AstraZeneca). This includes the lead asset EVT770, a novel beta cell regeneration factor, and a pipeline of selected additional secreted factors.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.